Akari Therapeutics, Plc
AKTX
$1.12
-$0.03-2.61%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
6/18/2025
-
GuruFocus
6/18/2025
-
GuruFocus
6/18/2025
-
GuruFocus
6/18/2025
-
The Fly
6/18/2025
-
Globe Newswire
6/9/2025
-
GuruFocus
6/9/2025
-
The Fly
5/29/2025
-
GuruFocus
5/29/2025
-
TipRanks Financial Blog
5/29/2025
-
The Fly
5/29/2025
-
Globe Newswire
5/22/2025
-
GuruFocus
5/22/2025
-
GuruFocus
5/22/2025
-
Globe Newswire
5/19/2025
-
Globe Newswire
5/17/2025
-
TipRanks Financial Blog
5/15/2025
-
GuruFocus
5/15/2025
-
GuruFocus
5/15/2025
-
The Fly
5/15/2025
-
Globe Newswire
5/1/2025
-
GuruFocus
5/1/2025
-
GuruFocus
5/1/2025
-
The Fly
5/1/2025
-
Globe Newswire
4/22/2025
-
GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, May 14, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 18 and 22 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
929 274 7510
Address
22 Boston Wharf Road
Boston, MA 02210
Boston, MA 02210
Country
Year Founded
--
Business Description
Sector
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes...
more